ONCODNA
7.4.2021 08:51:06 CEST | Business Wire | Press release
OncoDNA, a theranostic and genomic company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce a new collaboration that will revolutionize cancer care. The two companies agreed to consolidate their core technologies to enable the production of personalized vaccines for patients who have run out of treatment options.
With the COVID-19, the field of mRNA therapeutics has been moving faster than ever before. In oncology, personalized vaccines can help fight cancer by selectively boosting the immune system. These vaccines can teach the body to recognize and eliminate tumor-specific neoantigens.
OncoDNA and myNEO will leverage their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. While OncoDNA will perform whole genome and whole transcriptome sequencing, myNEO will handle the advanced interpretation of the sequenced data and design the optimal vaccine construct for maximum clinical benefit.
The project promises to guide patients through a completely personalized journey. The eligible patients would receive tailor-made vaccines as well as personalized follow-up by monitoring circulating tumor DNA after inoculation. With its OncoFOLLOW™ liquid biopsy, OncoDNA will help monitor the patient response and the evolution of the cancer very closely using personalized next-generation sequencing method.
“OncoDNA is delighted to jump with myNEO into this ambitious project. We stand at the forefront of innovation and the challenges ahead are herculean. Together we will work towards a world where patients with a hard-to-treat disease will have the opportunity to design their personalized elixirs. It may take years before this technology becomes a reality. However, the ongoing pilot tests on patients who do not respond to any therapy are showing promising results ”, commented Jean-Pol Detiffe, Chief Strategy & Innovation Officer and Founder of OncoDNA.
“Since day 1, myNEO’s mission has been to unlock the promise of immunotherapy via deep genomic and immune profiling of tumors,” described Cedric Bogaert, co-founder and CEO of myNEO. “Currently, our technology is used by biopharma partners to design the upcoming breakthrough immuno-oncology therapies. This project takes our ambition one step further in enabling OncoDNA’s vast network of clinicians and patients to directly benefit from this deep genomic and immune profiling. As such, this project holds great potential to make individualized immunotherapies more accessible to patients.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406006220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna to Power Apple Upgrade, a New Hardware Leasing Program Offered by Apple28.7.2026 14:15:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, today announced it would be the leasing provider behind the Apple Upgrade program, a new hardware leasing option available from Apple in the United States. Lease Apple hardware for low monthly payments Provided by Klarna, Apple Upgrade offers customers a new way to pay for eligible iPhone, Mac, iPad and Apple Watch. Customers can select from 12- and 24-month leasing options for iPhone and Apple Watch, and 24- and 36-month leasing options for Mac and iPad. In addition, when customers first enroll in Apple Upgrade, they can trade in an existing device to further lower their monthly payments during their initial lease term. The freedom to upgrade, return, or buy When the lease ends, customers choose what suits them: upgrade to the latest model1, purchase their device, or return it. A seamless checkout, and easy to manage payments Apple and Klarna have built an easy and seamless checkout experience which shows customers exactl
Third-Party EPDs Confirm C-Crete Cement Cuts Embodied Carbon by up to 95% — and It’s Already Being Poured Commercially28.7.2026 14:05:00 CEST | Press release
Two independently verified Environmental Product Declarations confirm cradle-to-gate carbon as low as 43.1 kg CO2-eq per metric ton. C-Crete’s platform technology turns a wide range of local rocks and industrial by-products into clinker-free cementitious binder — already in commercial use and adaptable to cement standards worldwide. C-Crete Technologies has published two Environmental Product Declarations (EPDs) verifying that its cements cut embodied carbon by up to 95% versus conventional portland cement. C-Crete’s technology converts a broad range of natural rocks and industrial by-products into cementitious binders with no clinker and no kiln, so production is inherently decentralized — and it is already being poured in commercial concrete today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728132467/en/ Representative C-Crete's project portfolio. More than 4000 tons of C-Crete's ultra-low carbon concrete have been
ExaGrid Releases Version 8.128.7.2026 14:00:00 CEST | Press release
Latest update includes support of Cohesity DataProtect, share quotas for MSPs, and NFS encryption over the wire ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced the release of ExaGrid software version 8.1. The latest version includes: Support for Cohesity DataProtect Uses S3 protocol. Supports Cohesity Cloud Archive Direct. ExaGrid further deduplicates Cohesity deduplicated data, cutting the storage footprint in half. ExaGrid works with Cohesity NetBackup for mixed NetBackup and DataProtect environments. NFS encrypted over the wire Available for backup apps that support NFS encryption over the wire. ExaGrid already supports encryption over the wire with other protocols such as the Veeam Data Mover, CIFS, and S3. Share Quota ExaGrid already tracks how much data is going into each share. Now, a Managed Service Provider (MSP) can s
Omilia Appoints David Ogden as VP of Revenue Operations28.7.2026 14:00:00 CEST | Press release
Enterprise SaaS revenue operations leader joins Omilia to build the operational backbone for its next phase of global growth Omilia, a global leader in Self-Learning Agentic CX, today announced the appointment of Dave Ogden as Vice President of Revenue Operations. Ogden will be responsible for scaling Omilia’s global revenue operations function spanning sales operations, forecasting, and commercial execution as the company accelerates growth across its key markets. In this role, Ogden will design and operate the revenue infrastructure that connects sales, marketing, and customer success, including forecasting, pipeline management, and deal desk operations. He joins as Omilia expands its direct and partner-led go-to-market across the US, Europe, Latin America and Australia, and will play a central role in ensuring that growth scales in a disciplined, data-driven way. Ogden brings more than 15 years of enterprise SaaS revenue and commercial operations experience. He spent nine years at F
Nine in 10 LPs More Likely to Commit to Funds Using Leverage When Disclosure is Clear28.7.2026 14:00:00 CEST | Press release
90% of LPs say adequate disclosure around fund-level leverage and liquidity tools would increase their likelihood to commit or re-upGPs use 2.4 liquidity tools on average as fund-level financing becomes embedded in private capital63% of GPs cite facility-data integration with accounting and investor reporting as a major operational challenge Fund-level leverage and liquidity tools have moved from specialist financing techniques to mainstream private capital infrastructure, according to new research from CSC, the leading provider of global business administration and compliance solutions. The findings show that limited partners (LPs) are increasingly open to the use of these tools when disclosure is clear, but general partners (GPs) face growing pressure to prove that the operating model behind them is controlled, transparent, and investor-ready. CSC¹ surveyed 300 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific. The report, Future Private Capital CFO 2026: How C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom